This month's regular Advanced Degrees Column in Contract Pharma Magazine, takes a look at some of the issues swirling around the controversial topic of follow-on biologics, or what some have referred to as "biogenerics." Also discussed are the measures certain segments of the logistics side of the industry have taken to stay ahead of the curve for when biosimilars' inevitable position in the market becomes a mainstream reality.

Subsequent market opinions, US regulatory debate, and comments can be found in The Editorial Section of the Boston Globe, Sunday, March 8, 2009.